ReviewOphthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)2026
Spectacle lenses for control of myopia progression in children.
Review in Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many new optical treatments have been developed recently to slow the progression of myopia. Most of these are based on theories of how myopia develops, such as poor accommodation, the type of peripheral refraction and image contrast (contrast modulation). Optically related treatments include spectacle lenses, contact lenses, orthokeratology, light therapies, more outdoor time, better interior lighting, indoor illumination, pharmacological intervention (through pupil and accommodation effects) and combination therapies. Current myopia-control spectacle lenses are described, including progressive addition, multisegment, annular cylinder, diffusion optics technology and concentric bifocals. Background is provided and a critical eye is passed over some of the designs. Short-term (12-month) efficacies for both axial length and myopia reduction in myopia-control spectacle wear, relative to single-vision lenses, are about 50%, as compared to 50%, 60% and 80% for contact lenses, orthokeratology and red-light therapy, respectively. Spectacle lens treatments for myopia control are safe, valuable tools in clinical practice. Further laboratory and clinical studies should help to clarify the nature of the mechanisms of action and improve efficacy.
Indexed as
Identifiers
42538488What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.